Patents by Inventor Nesrin S. Rechache

Nesrin S. Rechache has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DNA methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms
    Patent number: 9428813
    Abstract: Disclosed herein are methods for detecting, diagnosing and/or prognosing a malignant adrenocortical tumor. Also disclosed are methods of treating a malignant adrenocortical tumor, such as ACC. In some examples, the method of diagnosing and/or prognosing includes obtaining a sample comprising genomic DNA from a subject at risk of acquiring or suspected to have an adrenocortical tumor; isolating genomic DNA from the sample; and measuring the level of one or more methylated genomic CpG dinucleotide sequences in one or more of the adrenocortical genomic targets in the sample, wherein an increase in the level of methylation of the one or more genomic CpG dinucleotide sequences in the sample compared to a control indicates a malignant adrenocortical tumor.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: August 30, 2016
    Assignee: The United States of America, as Represented by the Secretary, Dept. of Health & Human Services
    Inventors: Electron Kebebew, Nesrin S. Rechache, Paul S. Meltzer, Yong-hong Wang
  • DNA METHYLATION ANALYSIS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF ADRENAL NEOPLASMS
    Publication number: 20150119350
    Abstract: Disclosed herein are methods for detecting, diagnosing and/or prognosing a malignant adrenocortical tumor. Also disclosed are methods of treating a malignant adrenocortical tumor, such as ACC. In some examples, the method of diagnosing and/or prognosing includes obtaining a sample comprising genomic DNA from a subject at risk of acquiring or suspected to have an adrenocortical tumor; isolating genomic DNA from the sample; and measuring the level of one or more methylated genomic CpG dinucleotide sequences in one or more of the adrenocortical genomic targets in the sample, wherein an increase in the level of methylation of the one or more genomic CpG dinucleotide sequences in the sample compared to a control indicates a malignant adrenocortical tumor.
    Type: Application
    Filed: March 12, 2013
    Publication date: April 30, 2015
    Applicant: The United States of America, as Represented by the Secretary, Dept. of Health & Human Services
    Inventors: Electron Kebebew, Nesrin S. Rechache, Paul S. Meltzer, Yong-hong Wang